NCT05270733View on ClinicalTrials.gov

Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

PHASE4RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Psoriasis
Interventions
DRUG

Ustekinumab

Subjects will receive ustekinumab for 8 weeks followed by guselkumab or risankizumab for 8 weeks.

Trial Locations (1)

44106

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

All Listed Sponsors
collaborator

LEO Foundation

UNKNOWN

collaborator

Case Western Reserve University

OTHER

lead

University Hospitals Cleveland Medical Center

OTHER